Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.,Neuro-Oncology

当前位置： X-MOL 学术 › Neuro Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
Neuro-Oncology ( IF 16.4 ) Pub Date : 2020-05-05 , DOI: 10.1093/neuonc/noaa113
Denise Bernhardt _{1,

2,

3} , Wolfgang Wick ₄ , Stephanie E Weiss ₅ , Arjun Sahgal ₆ , Simon S Lo ₇ , John H Suh ₈ , Eric L Chang ₉ , Matthew Foote ₁₀ , James Perry ₁₁ , Bernhard Meyer ₁₂ , Peter Vajkoczy ₁₃ , Patrick Y Wen ₁₄ , Christoph Straube _{1,

2,

3} , Steffi Pigorsch _{1,

2,

3} , Jan J Wilkens ₁ , Stephanie E Combs _{1,

2,

3}

Affiliation

Technical University of Munich (TUM), School of Medicine and Klinikum rechts der Isar, Department of Radiation Oncology, Munich.
Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Neuherberg.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich.
Neurology Clinic, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Department of Radiation Oncology, Sunnybrook Health Science Centre, Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Department of Radiation Oncology, Keck School of Medicine at University of Southern California, Los Angeles, California, USA.
Department of Radiation Oncology, Princess Alexandra Hospital, University of Queensland, Woolloongabba, QLD, Australia.
Division of Neurology, Department of MedicineOdette Cancer and Sunnybrook Health Science Centres, University of Toronto, Canada.
Technical University of Munich (TUM), School of Medicine and Klinikum rechts der Isar, Department of Neurosurgery, Munich.
Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany.
Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.

Because of the increased risk in cancer patients of developing complications caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), physicians have to balance the competing risks of the negative impact of the pandemic and the primary tumor disease. In this consensus statement, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGGs) during the coronavirus disease 2019 (COVID-19) pandemic.

中文翻译：

COVID-19 大流行期间的神经肿瘤学管理，重点关注 WHO III 级和 IV 级神经胶质瘤。

由于癌症患者出现由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的并发症的风险增加，医生必须平衡大流行和原发肿瘤疾病的负面影响的竞争风险。在这份共识声明中，一个国际专家组为 2019 年冠状病毒病 (COVID-19) 大流行期间患有高级别胶质瘤 (HGG) 的患者提出了缓解策略和治疗指南。

更新日期：2020-07-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11